KIROMIC BIOPHARMA

kiromic-biopharma-logo

Kiromic exists to create a robust diagnostic and therapeutic program for solid tumors and hematologic malignancies based on its portfolio of patented cancer-associated biomarkers and small molecules. Kiromic aims to develop clinical diagnostic tools for rapid detection of cancer-associated antigens, which may translate into earlier diagnosis and accurate monitoring of response to cancer treatments. Their cancer-associated biomarkers also allow for the design and development of personalized, cancer-specific targeted immunotherapy strategies that may improve patient outcomes and result in less suffering and longer survival times.

#SimilarOrganizations #People #Financial #Event #Website #More

KIROMIC BIOPHARMA

Social Links:

Industry:
Bioinformatics Biopharma Biotechnology Health Care Life Science Pharmaceutical Therapeutics

Founded:
2012-01-01

Address:
Houston, Texas, United States

Country:
United States

Website Url:
http://www.kiromic.com

Total Employee:
11+

Status:
Active

Contact:
806-252-5845

Email Addresses:
[email protected]

Total Funding:
53.24 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon WordPress Google Universal Analytics


Similar Organizations

adamas-pharmaceuticals-logo

Adamas Pharmaceuticals

Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.

apellis-pharmaceuticals-logo

Apellis Pharmaceuticals

Apellis Pharmaceuticals focusesย on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.

arcellx-logo

Arcellx

Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.

axcella-logo

Axcella

Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.

immunobiochem-corporation-logo

ImmunoBiochem Corporation

ImmunoBiochem is developing novel tumor microenvironment-targeted biological therapeutics for solid tumor indications.

nurix-therapeutics-logo

Nurix Therapeutics

Nurix Therapeutics is a biopharmaceutical company that focuses on the development and discovery of small molecule drugs.


Current Advisors List

michael-nagel_image

Michael Nagel Member Board Of Directors @ Kiromic Biopharma
Board_member
2020-01-01

Current Employees Featured

not_available_image

Karen R. Reeves, MD
Karen R. Reeves, MD Director @ Kiromic Biopharma
Director
2022-02-01

maurizio-chiriva-internati_image

Maurizio Chiriva-Internati
Maurizio Chiriva-Internati Chief Executive Officer & Founder @ Kiromic Biopharma
Chief Executive Officer & Founder
2016-02-01

leonardo-mirandola_image

Leonardo Mirandola
Leonardo Mirandola Chief Scientific Officer @ Kiromic Biopharma
Chief Scientific Officer
2022-07-01

daniel-clark_image

Daniel Clark
Daniel Clark Interim Chief Financial Officer @ Kiromic Biopharma
Interim Chief Financial Officer
2021-10-01

Founder


maurizio-chiriva-internati_image

Maurizio Chiriva-Internati

Stock Details


Company's stock symbol is NASDAQ:KRBP

Acquisitions List

Date Company Article Price
2021-06-14 In Silico Solutions In Silico Solutions acquired by Kiromic Biopharma N/A

Official Site Inspections

http://www.kiromic.com Semrush global rank: 6.92 M Semrush visits lastest month: 694

  • Host name: host2001.hostmonster.com
  • IP address: 67.20.76.53
  • Location: Provo United States
  • Latitude: 40.2342
  • Longitude: -111.6442
  • Metro Code: 770
  • Timezone: America/Denver
  • Postal: 84606

Loading ...

More informations about "Kiromic Biopharma"

Kiromic Biopharma - Crunchbase Company Profile & Funding

Kiromic exists to create a robust diagnostic and therapeutic program for solid tumors and hematologic malignancies based on its portfolio of patented cancer-associated biomarkers and โ€ฆSee details»

Kiromic Company Profile | Management and Employees List

Kiromic is in the process of developing ALEXIS, a multi-indication allogeneic CAR-T cell therapy platform that exploits the natural potency of g amma delta T-cells to target solid cancers. โ€ฆSee details»

KIROMIC, LLC - VentureRadar

" Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) platform to discover and develop cell and โ€ฆSee details»

Kiromic Biopharma - Org Chart, Teams, Culture & Jobs - The Org

Kiromic Biopharma is an immuno-oncology, target discovery, and gene editing company developing highly effective and safe tumor-specific cancer engineered immunotherapies to โ€ฆSee details»

Working At Kiromic: Company Overview and Culture - Zippia

Kiromic is a small professional company based in Houston, TX with only 50 employees and an annual revenue of $1.0B. Kiromic's Mission Statement Test products to be created by the joint โ€ฆSee details»

Kiromic - Golden

Organization. Company attributes. Industry. Molecular biology. 0. Bioinformatics. Healthcare. Pharmaceutical industry. Life science. ... Kiromic BioPharma, Inc. is an immuno-oncology โ€ฆSee details»

Kiromic Biopharma Company Profile - Office Locations ... - Craft

Sep 20, 2024 Kiromic BioPharma (formerly known as Kiromic) is a target discovery and gene editing company focusing on developing immuno-oncology therapeutics for the treatment of โ€ฆSee details»

Board of Directors - Kiromic BioPharma, Inc.

Mr. Bersani has served as a member of our Board since June 2020. The Company appointed Mr. Bersani Chief Executive Officer effective May 10, 2022.See details»

Overview - Kiromic

In order to overcome this challenge, Kiromic BioPharma, Inc. has developed a number of therapies to equip the immune system with the right tools for fighting cancer. Acute โ€ฆSee details»

Kiromic BioPharma Announces Changes in Management, Board of โ€ฆ

Jan 27, 2022 Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) platform to discover and โ€ฆSee details»

Kiromic - Company Profile - Tracxn

Dec 5, 2024 Kiromic - Developer of small molecules-based therapeutic solutions for the treatment of cancer. Public Company. Raised a total funding of $135K over 1 round. Founded โ€ฆSee details»

Kiromic Company Profile 2024: Stock Performance & Earnings

Kiromic General Information Description. Kiromic BioPharma Inc is a biotechnology company. It is an artificial intelligence (AI) driven, end-to-end allogeneic cell therapy company, currently โ€ฆSee details»

Leadership - Kiromic

Before joining Kiromic, Dr. Mirandola was a post-doctoral research scientist at Texas Tech University Health Sciences Center. He earned an M.S. in Medical Biotechnologies and a Ph.D. โ€ฆSee details»

Kiromic BioPharma, Inc.

Kiromic BioPharma, Inc. (Exact name of registrant as specified in its charter) De l aware 46-4762913 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer โ€ฆSee details»

Kiromic Biopharma - Contacts, Employees, Board Members

Organization. Kiromic Biopharma . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. ... Kiromic Biopharma has 1 โ€ฆSee details»

SEC.gov | SEC Charges Kiromic BioPharma and Two Former C-Suite ...

Dec 3, 2024 The Securities and Exchange Commission today filed settled charges against Houston-based biotherapeutics company Kiromic BioPharma, Inc., its former CEO, Maurizio โ€ฆSee details»

Kiromic Biopharma settles SEC charges over misleading investors ...

Dec 3, 2024 The SEC said Kiromic was not ordered to pay a civil penalty because the company had self-reported the incident, and Chiriva and Tontat agreed to pay civil penalties of $125,000 โ€ฆSee details»

Kiromic BioPharma Reports Fourth Quarter and Full-Year 2021 โ€ฆ

Dec 31, 2021 Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company using its proprietary DIAMOND ® artificial intelligence (AI) platform to discover and โ€ฆSee details»

Drug Development Pipeline - Kiromic

First patient Nov 2023 FTD Aug 2024 Expansion phase started in Sep 2024: Isocelโ„ข Alone or in combination with Low-Dose Radiation* Allogeneic, off-the-shelf, Viral vector-free GDT CAR-T โ€ฆSee details»

linkstock.net © 2022. All rights reserved